Abstract
The Liqui-Mass technology (also known as Liqui-Pellet technology) has shown promising results in terms of enhancing the drug release rate of water insoluble drugs in a simplistic approach. However, there is no current study on sustained-release formulation using the Liqui-Mass technology. In this study, an attempt was made to produce a sustained-release Liqui-Tablet for the first time using a matrix-based approach. The non-volatile co-solvent used in the investigation included Tween 80, Tween 20 and Kolliphor EL. The production of sustained-release propranolol hydrochloride Liqui-Tablet was successful, and data from the saturation solubility test and dissolution test did not show much difference among the mentioned non-volatile co-solvent. The best Liqui-Tablet formulation took 24 h for drug release to reach at around 100%. There seemed to be a synergistic retarding drug release effect when a non-volatile co-solvent and Eudragit RS PO were used together. The increase of Eudragit RS PO concentration increased the retardant effect. Kinetic drug release analysis suggests that the best formulation followed the Higuchi model. The flowability of pre-compressed Liqui-Tablet pellets had no issues and its size distribution was narrow. Liqui-Tablet was generally robust and most formulations passed the friability test. The study revealed that Liqui-Mass technology can be employed to sustain drug release.
Highlights
Liqui-Mass technology, or sometimes referred to as Liqui-Pellet technology, is a recently developed oral drug delivery system, which was first filed for a patent in 2018 and published internationally in 2020 [1]
Liqui-Pellet and liquisolid technologies share some similarities, but there are crucial differences separating them. Both contain active pharmaceutical ingredient (API) that is solubilised in a liquid vehicle and incorporated into carrier and coating material; the admixture for liquisolid formulation is under liquisolid system, which is an extensively used and defined term in liquisolid technology
In a study by Javadzadeh et al [17], other liquid vehicles such as propylene glycol, PEG 400, PEG 200 and glycerine were used; the results showed propranolol hydrochloride had the lowest solubility in Tween 80
Summary
Liqui-Mass technology, or sometimes referred to as Liqui-Pellet technology, is a recently developed oral drug delivery system, which was first filed for a patent in 2018 and published internationally in 2020 [1]. Liqui-Pellet and liquisolid technologies share some similarities, but there are crucial differences separating them Both contain API that is solubilised in a liquid vehicle and incorporated into carrier and coating material; the admixture for liquisolid formulation is under liquisolid system, which is an extensively used and defined term in liquisolid technology. The term “liquisolid systems” refers to powdered forms of liquid medications formulated by converting liquid lipophilic drugs, or drug suspensions or solutions of water-insoluble solid drugs in suitable non-volatile solvent systems, into “dry” (i.e., dry-looking), nonadherent, free-flowing and readily compressible powder admixtures by blending with a selected carrier and coating materials [14]. The investigation aimed to produce a sustained release propranolol Liqui-Tablet through utilizing the non-disintegrating MCC-based pellets, retarding agent (Eudragits RS PO) and liquid vehicles. The non-volatile co-solvent reduced the API solubility, and the retardant polymer was within the whole pellet structure, which was com of 13 pressed into Liqui-Tablet
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
